4,309
Views
92
CrossRef citations to date
0
Altmetric
Review

The Conundrum of ‘Long-COVID-19ʹ: A Narrative Review

ORCID Icon, ORCID Icon, ORCID Icon, , , , , , , , , , , , & show all
Pages 2491-2506 | Published online: 14 Jun 2021

References

  • Garg S, Garg M, Prabhakar N, Malhotra P, Agarwal R. Unraveling the mystery of Covid-19 cytokine storm: from skin to organ systems. Dermatol Ther. 2020;33(6):1385–1389. doi:10.1111/dth.13859
  • Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26:1017–1032. doi:10.1038/s41591-020-0968-3
  • WHO [homepage on the internet]. Coronavirus disease (COVID-19). [ updated November 10, 2020]. Available from: https://www.who.int/news-room/q-a-detail/coronavirus-disease-covid-19/. Accessed December 14, 2020.
  • Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136. doi:10.1136/bmj.n136
  • Mahase E. Covid-19: what do we know about “long covid”? BMJ. 2020;370:m2815. doi:10.1136/bmj.m2815
  • Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026. doi:10.1136/bmj.m3026
  • Callard F, Perego E. How and why patients made Long Covid. Soc Sci Med. 2021;268:113426. doi:10.1016/j.socscimed.2020.113426
  • Worldometer [Homepage on internet]. Coronavirus update. Available from: https://www.worldometers.info/coronavirus/. Accessed May 15, 2021.
  • Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv [Preprint]. 2021. doi:10.1101/2021.01.27.21250617
  • Barman MP, Rahman T, Bora K, Borgohain C. COVID-19 pandemic and its recovery time of patients in India: a pilot study. Diabetes Metab Syndr. 2020;14(5):1205–1211. doi:10.1016/j.dsx.2020.07.004
  • Nehme M, Braillard O, Alcoba G, et al. COVID-19 symptoms: longitudinal evolution and persistence in outpatient settings. Ann Intern Med. 2020.
  • Carfì A, Bernabei R, Landi F. Gemelli against COVID-19 post-acute care study group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603–605. doi:10.1001/jama.2020.12603
  • Office for National Statistics. The prevalence of long COVID symptoms and COVID-19 complications. [ updated December 16, 2020]. Available from: https://www.ons.gov.uk/. Accessed February 2, 2021.
  • Goërtz YMJ, Van Herck M, Delbressine JM, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6:00542–2020. doi:10.1183/23120541.00542-2020
  • Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020;81(6):e4–e6. doi:10.1016/j.jinf.2020.08.029
  • Xiong Q, Xu M, Li J, et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect. 2021;27(1):89–95. doi:10.1016/j.cmi.2020.09.023
  • Dennis A, Wamil M, Alberts J; COVERSCAN study investigators. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open. 2021;11(3):e048391. doi:10.1136/bmjopen-2020-048391
  • Carvalho-Schneider C, Laurent E, Lemaignen A, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2021;27(2):258–263. doi:10.1016/j.cmi.2020.09.052
  • Davis HE, Assaf GS, McCorkell L, et al. Characterizing Long COVID in an international cohort: 7 Months of symptoms and their impact. medRxiv [Preprint]. 2020.
  • López Castro J. Post-COVID-19 syndrome (PC19S): chronic reactive endotheliitis and disseminated vascular disease. Acta Med Port. 2020;33(12):859. doi:10.20344/amp.14612
  • Afrin LB, Weinstock LB, Molderings GJ. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020;100:327–332. doi:10.1016/j.ijid.2020.09.016
  • Sollini M, Ciccarelli M, Cecconi M, et al. Vasculitis changes in COVID-19 survivors with persistent symptoms: an [18F]FDG-PET/CT study. Eur J Nucl Med Mol Imaging. 2020;30:1–7.
  • Aragão MFVV, Leal MC, Cartaxo Filho OQ, Fonseca TM, Valença MM. Anosmia in COVID-19 associated with injury to the olfactory bulbs evident on MRI. AJNR Am J Neuroradiol. 2020;41:1703–1706. doi:10.3174/ajnr.A6675
  • Strauss SB, Lantos JE, Heier LA, Shatzkes DR, Phillips CD. Olfactory bulb signal abnormality in patients with COVID-19 who present with neurologic symptoms. AJNR Am J Neuroradiol. 2020;41:1882–1887. doi:10.3174/ajnr.A6751
  • Roncati L, Ligabue G, Fabbiani L, et al. Type 3 hypersensitivity in COVID-19 vasculitis. Clin Immunol. 2020;217:108487. doi:10.1016/j.clim.2020.108487
  • Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155–162. doi:10.1097/BOR.0000000000000776
  • Hussein HM, Rahal EA. The role of viral infections in the development of autoimmune diseases. Crit Rev Microbiol. 2019;45:394–412. doi:10.1080/1040841X.2019.1614904
  • Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev. 2006;19:80–94. doi:10.1128/CMR.19.1.80-94.2006
  • Ehrenfeld M, Tincani A, Andreoli L, et al. Covid-19 and autoimmunity. Autoimmun Rev. 2020;19:102597. doi:10.1016/j.autrev.2020.102597
  • Zhou Y, Han T, Chen J, et al. Clinical and autoimmune characteristics of severe and critical cases of COVID-19. Clin Transl Sci. 2020;13:1077–1086. doi:10.1111/cts.12805
  • Herzog EL, Mathur A, Tager AM, et al. Interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol. 2014;66:1967–1978. doi:10.1002/art.38702
  • Zuo Y, Estes SK, Ali RA, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020;12(570):eabd3876. doi:10.1126/scitranslmed.abd3876
  • Zuo Y, Zuo M, Yalavarthi S, et al. Neutrophil extracellular traps and thrombosis in COVID-19. medRxiv. 2020.
  • Ye G, Pan Z, Pan Y, et al. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. J Infect. 2020;80(5):14–17. doi:10.1016/j.jinf.2020.03.001
  • Investigative criteria for suspected cases of SARS-CoV-2 reinfection (ICR). https://www.cdc.gov/coronavirus/2019-ncov/php/invest-criteria.html. Accessed February 3, 2021.
  • Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(8):1200–1204. doi:10.1038/s41591-020-0965-6
  • Wong AW, Shah AS, Johnston JC, Carlsten C, Ryerson CJ. Patient-reported outcome measures after COVID-19: a prospective cohort study. Eur Respir J. 2020;56(5):2003276. doi:10.1183/13993003.03276-2020
  • Chopra V, Flanders SA, O’Malley M, Malani AN, Prescott HC. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med. 2020.
  • Garg M, Prabhakar N, Bhalla AS, et al. Computed tomography chest in COVID-19: when & why? Indian J Med Res. 2021;153(1–2):86–92. doi:10.4103/ijmr.IJMR_3669_20
  • Garg M, Gupta P, Maralakunte M, et al. Diagnostic accuracy of CT and radiographic findings for novel coronavirus 2019 pneumonia: systematic review and meta-analysis. Clin Imaging. 2020;72:75–82. doi:10.1016/j.clinimag.2020.11.021
  • Wang Y, Dong C, Hu Y, et al. Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: a longitudinal study. Radiology. 2020;296(2):E55–E64. doi:10.1148/radiol.2020200843
  • Udwadia ZF, Koul PA, Richeldi L. Post-COVID lung fibrosis: the tsunami that will follow the earthquake. Lung India. 2021;38:S41–S47. doi:10.4103/lungindia.lungindia_818_20
  • Chun HJ, Coutavas E, Pine A, et al. Immuno-fibrotic drivers of impaired lung function in post-COVID-19 syndrome. medRxiv [Preprint]. 2021. doi:10.1101/2021.01.31.21250870
  • Mo X, Jian W, Su Z, et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J. 2020;55(6):2001217. doi:10.1183/13993003.01217-2020
  • Mandal S, Barnett J, Brill SE, et al.; ARC Study Group. ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2020. doi:10.1136/thoraxjnl-2020-215818
  • Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):819–824. doi:10.1001/jamacardio.2020.1096
  • Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116:1097–1100. doi:10.1093/cvr/cvaa078
  • Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–1418. doi:10.1016/S0140-6736(20)30937-5
  • Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. doi:10.1016/S2213-2600(20)30076-X
  • Huang L, Zhao P, Tang D, et al. Cardiac involvement in patients recovered from COVID-2019 identified using magnetic resonance imaging. JACC Cardiovasc Imaging. 2020;13(11):2330–2339. doi:10.1016/j.jcmg.2020.05.004
  • Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(11):1265–1273. doi:10.1001/jamacardio.2020.3557
  • Rajpal S, Tong MS, Borchers J, et al. Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection. JAMA Cardiol. 2021;6(1):116–118. doi:10.1001/jamacardio.2020.4916
  • Dani M, Dirksen A, Taraborrelli P, et al. Autonomic dysfunction in ‘long COVID’: rationale, physiology and management strategies. Clin Med. 2021;21(1):e63–e67. doi:10.7861/clinmed.2020-0896
  • McMahon DE, Gallman AE, Hruza GJ, et al. Long COVID in the skin: a registry analysis of COVID-19 dermatological duration. Lancet Infect Dis. 2021;21(3):313–314. doi:10.1016/S1473-3099(20)30986-5
  • Mehta P, Bunker CB, Ciurtin C, et al. Chilblain-like acral lesions in long COVID-19: management and implications for understanding microangiopathy. Lancet Infect Dis. 2021. doi:10.1016/S1473-3099(21)00133-X
  • Suchonwanit P, Leerunyakul K, Kositkuljorn C. Cutaneous manifestations in COVID-19: lessons learned from current evidence. J Am Acad Dermatol. 2020;83:e57–e60. doi:10.1016/j.jaad.2020.04.094
  • Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683–690. doi:10.1001/jamaneurol.2020.1127
  • Stefano GB, Ptacek R, Ptackova H, Martin A, Kream RM. Selective neuronal mitochondrial targeting in SARS-CoV-2 infection affects cognitive processes to induce ‘Brain Fog’ and results in behavioral changes that favor viral survival. Med Sci Monit. 2021;27:e930886. doi:10.12659/MSM.930886
  • Lechien JR, Chiesa-Estomba CM, De Siati DR, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277(8):2251–2261. doi:10.1007/s00405-020-05965-1
  • Lu Y, Li X, Geng D, et al. Cerebral micro-structural changes in COVID-19 patients - an MRI-based 3-month follow-up study. EClinicalMedicine. 2020;25:100484. doi:10.1016/j.eclinm.2020.100484
  • Helms J, Kremer S, Merdji H, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med. 2020;382(23):2268–2270. doi:10.1056/NEJMc2008597
  • Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611–627. doi:10.1016/S2215-0366(20)30203-0
  • Parker AM, Sricharoenchai T, Raparla S, et al. Posttraumatic stress disorder in critical illness survivors: a metaanalysis. Crit Care Med. 2015;43:1121–1129. doi:10.1097/CCM.0000000000000882
  • Nikayin S, Rabiee A, Hashem MD, et al. Anxiety symptoms in survivors of critical illness: a systematic review and meta-analysis. Gen Hosp Psychiatry. 2016;43:23–29. doi:10.1016/j.genhosppsych.2016.08.005
  • Rabiee A, Nikayin S, Hashem MD, et al. Depressive symptoms after critical illness: a systematic review and meta-analysis. Crit Care Med. 2016;44:1744–1753. doi:10.1097/CCM.0000000000001811
  • Wohleb ES, Franklin T, Iwata M, Duman RS. Integrating neuroimmune systems in the neurobiology of depression. Nat Rev Neurosci. 2016;17:497–511. doi:10.1038/nrn.2016.69
  • Hopkins RO, Weaver LK, Pope D, et al. Neuropsychological sequelae and impaired health status in survivors of severe acute respiratory distress syndrome. Am J Respir Crit Care Med. 1999;160:50–56. doi:10.1164/ajrccm.160.1.9708059
  • Sansone A, Mollaioli D, Ciocca G, et al. Addressing male sexual and reproductive health in the wake of COVID-19 outbreak. J Endocrinol Invest. 2021;44(2):223–231. doi:10.1007/s40618-020-01350-1
  • Anwar S, Acharya S, Shabih S, Khabut A. Acute limb ischemia in COVID-19 disease: a mysterious coagulopathy. Cureus. 2020;12(7):e9167.
  • Acharya S, Anwar S, Siddiqui FS, Shabih S, Manchandani U, Dalezman S. Renal artery thrombosis in COVID-19. IDCases. 2020;22:e00968. doi:10.1016/j.idcr.2020.e00968
  • Marinho PM, Marcos AAA, Romano AC, Nascimento H, Jr BR. Retinal findings in patients with COVID-19. Lancet. 2020;395(10237):1610. doi:10.1016/S0140-6736(20)31014-X
  • Fernandez CE, Franz CK, Ko JH, et al. Imaging review of peripheral nerve injuries in patients with COVID-19. Radiology. 2021;298(3):E117–E130. doi:10.1148/radiol.2020203116
  • Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323:1239–1242. doi:10.1001/jama.2020.2648
  • Ojo AS, Balogun SA, Williams OT, Ojo OS. Pulmonary fibrosis in COVID-19 survivors: predictive factors and risk reduction strategies. Pulm Med. 2020;2020:6175964. doi:10.1155/2020/6175964
  • Sokolowska M, Lukasik ZM, Agache I, et al. Immunology of COVID-19: mechanisms, clinical outcome, diagnostics, and perspectives-a report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy. 2020;75:2445–2476. doi:10.1111/all.14462
  • Radzikowska U, Ding M, Tan G, et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy. 2020;75:2829–2845. doi:10.1111/all.14429
  • Dong X, Cao YY, Lu XX, et al. Eleven faces of coronavirus disease 2019. Allergy. 2020;75:1699–1709. doi:10.1111/all.14289
  • Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20(6):669–677. doi:10.1016/S1473-3099(20)30243-7
  • Richardson S, Hirsch JS, Narasimhan M; the Northwell COVID-19 Research Consortium. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area. JAMA. 2020;323(20):2052–2059. doi:10.1001/jama.2020.6775
  • Tenforde MW, Kim SS, Lindsell CJ; CDC COVID-19 Response Team; IVY Network Investigators. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(30):993–998. doi:10.15585/mmwr.mm6930e1
  • Sudre CH, Murray B, Varsaysky T, et al. Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the covid symptoms study app. medRxiv. 2020.
  • Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case surveillance - United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(24):759–765. doi:10.15585/mmwr.mm6924e2
  • Liao D, Zhou F, Luo L, et al. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol. 2020;7(9):e671–e678. doi:10.1016/S2352-3026(20)30217-9
  • Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636–1643. doi:10.1038/s41591-020-1051-9
  • Spoto S, Agrò FE, Sambuco F, et al. High value of mid-regional proadrenomedullin in COVID-19: a marker of widespread endothelial damage, disease severity, and mortality. J Med Virol. 2021;93(5):2820–2827. doi:10.1002/jmv.26676
  • Das KM, Lee EY, Singh R, et al. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J Radiol Imaging. 2017;27(3):342–349. doi:10.4103/ijri.IJRI_469_16
  • Oeckler RA, Hubmayr RD. Ventilator-associated lung injury: a search for better therapeutic targets. Eur Respir J. 2007;30:1216–1226. doi:10.1183/09031936.00104907
  • Yu M, Liu Y, Xu D, et al. Prediction of the development of pulmonary fibrosis using serial thin-section CT and Clinical features in patients discharged after treatment for COVID-19 pneumonia. Korean J Radiol. 2020;21(6):746–755. doi:10.3348/kjr.2020.0215
  • Zhou P, Liu Z, Chen Y, et al. Bacterial and fungal infections in COVID-19 patients: a matter of concern. Infect Control Hosp Epidemiol. 2020;41(9):1124–1125. doi:10.1017/ice.2020.156
  • George PM, Barratt SL, Condliffe R, et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020;75(11):1009–1016. doi:10.1136/thoraxjnl-2020-215314
  • George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020;8:807–815. doi:10.1016/S2213-2600(20)30225-3
  • Mohamed AA, Alawna M. Role of increasing the aerobic capacity on improving the function of immune and respiratory systems in patients with coronavirus (COVID-19): a review. Diabetes Metab Syndr. 2020;14(4):489–496. doi:10.1016/j.dsx.2020.04.038